Topics

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq pic.twitter.com/sVTCKkGshh

07:19 EDT 3 Oct 2019 | Pharmafile

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq 

Original Article: Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq pic.twitter.com/sVTCKkGshh

NEXT ARTICLE

More From BioPortfolio on "Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq pic.twitter.com/sVTCKkGshh"

Quick Search

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...